MASTERCARD-INVESTOR
30.5.2024 11:36:34 CEST | Business Wire | Press release
Mastercard today announced the opening of its European Cyber Resilience Centre (ECRC) at its European Headquarters reaffirming the company’s commitment to combatting cyber threats and enhancing resilience in the region. The new state-of-the-art centre will sharpen defenses against cyber threats, speed up response times and serve as a hub for thought leadership in cybersecurity, fostering collaboration between the public and private sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530937171/en/
Mastercard European Cyber Resilience Centre Opening in Waterloo, Belgium. (From left to right) Michael Miebach, Chief Executive Officer, Mastercard, Mathieu Michel, Belgian State Secretary for Digitalisation, Mark Barnett, President, Mastercard Europe, Catherine De Bolle, Executive Director, Europol. Photo by: Nicolas Peeters. (Photo: Business Wire)
With continuous digitization and unprecedented levels of connectivity, cybercrime presents a shared challenge across all organizations. Fraudsters are using technology in more innovative and sophisticated ways to try and harm consumers and businesses. Cybercrime has turned into a global economy now estimated to be worth trillions of euros.
To address this ever-evolving threat landscape, the ECRC brings together partners from across the public and private sectors. By leveraging its facilities and diverse talent pool, it facilitates collaboration with national cyber intelligence centres, law enforcement agencies, and industry bodies across Europe.
"In today’s hyperconnected world, cybercrime is evolving and so are we. This centre will bring together the brightest minds from business, government and other sectors to stay ahead of threats and make the digital world as secure as possible. Afterall, the work to ensure people can trust that they are safe online doesn’t stop at our four walls — or our firewalls," said Michael Miebach, CEO, Mastercard.
The Centre bolsters Mastercard’s ability to combat cyber threats across the digital ecosystem and helps it protect, detect, and respond to attacks. It fosters deeper connections with customers, partners, and stakeholders and drives collaboration across the region, enhancing resilience.
The Mastercard European Cyber Resilience Centre includes a Fusion Centre, the heart of Mastercard’s organizational incident response, and a Digital Forensics Lab in addition to representatives from more than 20 teams - all crucial to running an effective Resilience Centre.
"At Europol, we are strong believers that no single actor, sector or nation, can face the threats of cybercriminals alone. Each of us has a complementary role to play. By bringing together all relevant actors, the European Cyber Resilience Centre has the potential to bring excellence into our cross-sectoral collaboration," said Catherine De Bolle, Executive Director, Europol.
"It is with great pride that I am here today for the inauguration of the Mastercard European Cyber Resilience Centre. I am delighted that Belgium has been chosen to host this first centre in Europe dedicated to cybersecurity for Mastercard, and even more so because it will be established in the heart of Walloon Brabant. We live in a world where cyber threats are omnipresent and constantly evolving. Cyberattacks know no borders and affect all sectors of our society, from the public to the private sector, from critical infrastructures to ordinary citizens. It is therefore imperative that we unite to meet these challenges with determination and efficiency. This event marks a significant milestone in our shared commitment to strengthening cybersecurity in Europe and Belgium. The European Cyber Resilience Centre represents a key initiative to promote collaboration between the public and private sector, as well as regulatory bodies. By working hand in hand, we can significantly improve our ability to prevent, detect and respond to cyber threats," said Mathieu Michel, Belgian Secretary of State for Digitalization.
The commitment to European security is reflective of Mastercard's role in powering economies and empowering people. This is underscored by its robust infrastructure, which facilitated the protection of 143 billion transactions in 2023 alone. Upholding high standards of privacy, data responsibility, and cybersecurity, Mastercard continues to deliver seamless and secure transactions while safeguarding customer information.
About Mastercard (NYSE: MA), www.mastercard.com
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530937171/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
